BioCentury
ARTICLE | Translation in Brief

Super-additive silencing

Tekmira's dual-component RNAi lowers triglycerides

April 9, 2015 7:00 AM UTC

Tekmira Pharmaceuticals Corp. has a dual-targeting RNAi that could treat hypertriglyceridemia more effectively than therapeutics that silence either target alone.

The two-component product, TKM-HTG, contains RNAi components that separately target apolipoprotein C-III (APOC3; APOCIII) and angiopoietin-like 3 (ANGPTL3) - two genes expressed in the liver that encode proteins involved in lipid metabolism...